Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | INXB | Stock Option (right to buy) | Award | $0 | +30K | $0.00 | 30K | May 30, 2024 | Common Stock | 30K | $15.86 | Direct | F1, F2 |
Id | Content |
---|---|
F1 | This stock option was granted following the consummation of the merger of Inhibrx, Inc. with a wholly owned indirect subsidiary of Sanofi. |
F2 | This stock option will be fully exercisable on May 30, 2025, subject to the reporting person's continued service through such date. |